Investor Relations

Corporate ProfileNuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge, neural-interface technologies for the neuroscience pre-clinical research market.

On March 14, 2016, Nuvectra Corporation completed its spin-off from Greatbatch, Inc. into an independent, publicly-traded neurostimulation medical device company. The company is headquartered in Plano, Texas, with additional locations in Denver, Ann Arbor, and Minneapolis.

Nuvectra currently trades on the NASDAQ Global Market (NASDAQ) under the ticker symbol "NVTR."


Stock Quote NVTR (Common Stock) $13.76 - 0.28 (1.99%)
ExchangeNASDAQ
Volume30,333
Today's Open$14.28
Previous Close$14.04
Data as of 10/20/17 3:59 p.m. ET
Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart
Stock chart for: NVTR.O.  Currently trading at $13.76 with a 52 week high of $15.00 and a 52 week low of $4.63.

Recent News

September 11, 2017

First Spinal Cord Stimulator Implant Placed in Northern California by Dr. Goldthwaite Brings Pain Relief and Reduces Opioid Use for Local Injured Veteran

PLANO, Texas, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Noel Goldthwaite, MD, senior surgeon and founding member at SpineCare Medical Group, Inc., is the first physician in northern California to implant Nuvectra’s Algovita® Spinal Cord Stimulation System, which successfully treated a local injured veteran’s chronic pain and led to his significant reduction in opioid use. The Nuvectra Algovita SCS System is a powerful and versatile spinal cord stimulation system that includes the smallest patient con

Read More >

August 30, 2017

Nuvectra to Participate in Morgan Stanley Global Healthcare Conference

PLANO, Texas, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & CFO, are scheduled to participate at the Morgan Stanley Global Healthcare Conference in New York, NY. Event:       Morgan Stanley Global Healthcare Conference Date:         Monday, September 11, 2017 The Company will be participating in one-on-one investor m

Read More >


Investor Contact

The Ruth Group
Brian Johnston
Zack Kubow
investors@nuvectramed.com

Events
There are currently no events scheduled.